List of Excipients in Branded Drug KYMRIAH

Kymriah Excipient Strategy and Commercial Opportunities in CAR-T Cell Therapy

Last updated: August 9, 2026

Kymriah’s excipient strategy is built around cryopreservation and cell viability rather than conventional oral or injectable drug delivery. The commercial opportunity is concentrated in GMP-grade dimethyl sulfoxide, human serum albumin, cryopreservation media, container-closure systems, cold-chain services, analytical testing, and process platforms that improve post-thaw cell recovery. Kymriah is a patient-specific autologous CAR-T product, so excipients must support a living cellular product through collection, manufacturing, freezing, shipment, thawing, and infusion.

The product’s main regulatory and commercial moat is the manufacturing process and therapeutic franchise, not the excipient composition alone. The US FDA approved Kymriah, tisagenlecleucel, in 2017 for certain B-cell malignancies and later expanded its indications. Kymriah is regulated as a biologic under a biologics license application, not as a conventional small-molecule drug listed in the Orange Book.[1]

What excipients are used in Kymriah?

Kymriah is supplied as a cryopreserved suspension of genetically modified autologous T cells. The US prescribing information identifies a cryopreservation medium containing dimethyl sulfoxide and human serum albumin.[1] Product presentations and regional documents may provide further compositional detail, but the commercial formulation strategy is clear: protect viable CAR-positive T cells during controlled-rate freezing, long-term storage, transport, thawing, and administration.

Core excipient functions

Excipient or material	Primary function in Kymriah-type products	Commercial relevance
Dimethyl sulfoxide, or DMSO	Cryoprotectant that limits intracellular ice formation and membrane damage	High-volume, GMP-grade supply; impurity and residual-level control
Human serum albumin, or HSA	Protein stabilizer and membrane-protective component	Requires plasma-derived or recombinant sourcing, viral safety controls, and supply assurance
Saline or compatible aqueous vehicle	Supports osmolality and administration compatibility where used in the final product or infusion process	Standardized sterile formulation and container compatibility
Dextran or related polymer, where included in a regional or process-specific formulation	May contribute to cryoprotection, osmotic control, or cell recovery	Opportunity for qualified specialty excipient suppliers
Cryobag and tubing materials	Not an excipient, but directly affects product stability and extractables profile	High-value component of the container-closure system
Controlled-rate freezing medium	Process material used to achieve reproducible freezing	Opportunity for qualified, ready-to-use cell-therapy media

DMSO and HSA are the most commercially important named formulation components in the US label. DMSO concentration, exposure time, cooling rate, thawing conditions, and post-thaw handling can affect viability and potency. A supplier that changes the grade, source, concentration, or manufacturing process may trigger comparability, qualification, and regulatory work.

How does Kymriah’s formulation differ from conventional drug excipients?

Kymriah does not use excipients primarily to control dissolution, gastrointestinal absorption, tablet compression, or sustained release. The formulation must preserve a living cell population with a defined phenotype and functional potency.

This creates a different excipient risk profile:

1. Cell survival after thawing is a critical quality attribute.
2. Residual DMSO can contribute to tolerability concerns during infusion.
3. HSA introduces source, viral safety, and supply-chain considerations.
4. The final container must withstand ultra-low-temperature storage and shipment.
5. Changes to excipient grade or supplier can affect cell recovery, phenotype, potency, and comparability.
6. The formulation is inseparable from the manufacturing and logistics process.

For conventional drugs, an excipient change may be assessed through dissolution and stability testing. For CAR-T products, the assessment can require viability, recovery, phenotype, transduction-related attributes, potency, sterility, endotoxin, mycoplasma, and replication-competent viral testing, depending on the change and the product’s control strategy.[2]

What excipient opportunities exist around Kymriah?

The highest-value opportunities are in qualified materials and process systems rather than commodity excipient sales.

GMP-grade DMSO

DMSO is widely available, but cell-therapy manufacturers require grades appropriate for sterile pharmaceutical processing. Commercial differentiation can include:

• Low endotoxin and low bioburden specifications
• Low impurity and trace-metal profiles
• Sterile, ready-to-use packaging
• Lot-to-lot consistency
• Documentation supporting extractables, leachables, and container compatibility
• Supply agreements with dual-site manufacturing
• Packaging in small-volume, closed-system formats

DMSO suppliers can also develop formulations optimized for specific cell types, freezing rates, or automated manufacturing platforms. The strongest commercial position is created when a supplier’s DMSO is embedded in a validated process rather than purchased as a freely interchangeable raw material.

Human serum albumin

HSA is more strategically sensitive than many conventional excipients. Buyers may prefer a defined supply chain with robust viral safety documentation, global availability, and manufacturing continuity.

Commercial opportunities include:

• Plasma-derived HSA with cell-therapy-specific documentation
• Recombinant albumin as a potential alternative
• Low-endotoxin, low-particulate grades
• Ready-to-use sterile solutions
• Closed-system dispensing
• Formulation support for reduced protein concentration
• Comparability packages for switching from plasma-derived to recombinant albumin

The main barriers are qualification time, regulatory documentation, and the need to show that a source change does not affect cell viability or potency.

Defined and serum-free cryopreservation media

A major development opportunity is the replacement or reduction of animal-derived and plasma-derived components. Defined cryopreservation media may improve supply transparency and simplify global manufacturing, but the product must maintain equivalent or superior post-thaw performance.

Potential product claims include:

• Improved viable cell recovery
• Lower residual DMSO burden
• Reduced aggregation
• Better recovery after extended frozen storage
• Compatibility with automated filling and freezing
• Use across autologous and allogeneic CAR-T programs

A successful media platform can generate revenue across multiple cell therapies, while a single-excipient product is more exposed to price competition.

Cryobags and fluid-path components

The container-closure system is a major opportunity because it must maintain sterility and integrity at cryogenic temperatures. Relevant products include:

• Cryogenic infusion bags
• Sterile tubing sets
• Transfer devices
• Weldable and aseptic connectors
• Temperature-monitoring systems
• Secondary containment
• Validated shipping containers

These products are often qualified as part of the manufacturing process and can have substantial switching costs. Their value is increased when the supplier provides extractables and leachables data, integrity testing, transport validation, and compatibility with automated filling systems.

What formulation patents protect Kymriah?

Kymriah’s principal IP position is expected to center on the CAR construct, engineered T-cell composition, methods of manufacture, cell expansion, transduction, and treatment methods. The cryopreservation excipients alone are unlikely to provide the principal exclusivity barrier.

Kymriah is not a small-molecule product with a conventional Orange Book patent listing. It is licensed under the FDA’s biologics framework, and the relevant patent landscape may include patents assigned to Novartis, the University of Pennsylvania, licensors, platform developers, and other parties involved in CAR-T technology. Patent rights can cover:

• Anti-CD19 CAR structures
• Costimulatory domains
• Nucleic acids encoding the CAR
• Viral-vector production and transduction
• T-cell activation and expansion
• Cell-composition claims
• Cryopreservation or formulation processes
• Methods of treating leukemia and lymphoma
• Manufacturing controls and release testing

A specific Kymriah patent expiration date cannot be inferred from the FDA label or from biologic exclusivity. Patent term depends on the individual patent, terminal disclaimers, patent-term adjustment, patent-term extension, continuations, and jurisdiction. The practical commercial date for conventional biosimilar competition is also distinct from the expiration of any one patent.

When does Kymriah lose regulatory exclusivity?

Kymriah received FDA approval on August 30, 2017. The Biologics Price Competition and Innovation Act generally provides 12 years of reference-product exclusivity for licensed biologics, subject to statutory rules and pediatric exclusivity adjustments.[3] On that basis, the principal US reference-product exclusivity period runs toward 2029.

Milestone	Date or status
FDA approval	August 30, 2017
Initial indication	Pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Later FDA indication	Adult patients with relapsed or refractory large B-cell lymphoma after at least two lines of systemic therapy
Additional FDA indication	Adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
Biologic reference exclusivity	Generally associated with a 12-year period from initial licensure, subject to statutory adjustments
Orange Book status	Not applicable as a conventional small-molecule listing
Biosimilar interchangeability	No conventional interchangeable biosimilar pathway has produced a substitute Kymriah product
Current competitive threat	Other CAR-T therapies, antibody-drug conjugates, bispecific antibodies, manufacturing alternatives, and treatment-center capacity

FDA exclusivity does not prevent competing CAR-T products from entering under their own biologics license applications. It also does not eliminate patent-based litigation risk.

Is Kymriah exposed to biosimilar or generic competition?

Kymriah has no traditional generic substitution pathway. A small-molecule ANDA applicant cannot copy tisagenlecleucel. A biosimilar applicant would need to demonstrate biosimilarity to a complex, patient-specific living-cell product under the 351(k) pathway. The scientific and regulatory burden is materially different from that for a protein biologic.

Potential competitors are more likely to enter through:

• A separate CAR-T biologics license application
• An alternative CD19-directed CAR-T product
• An allogeneic or off-the-shelf cell therapy
• A different cellular manufacturing platform
• A non-cellular treatment such as a bispecific antibody
• A next-generation product with improved logistics or safety

This reduces the importance of conventional formulation patents while increasing the importance of manufacturing patents, clinical differentiation, and treatment-center integration.

What manufacturing and IP barriers protect Kymriah?

The main barriers are operational and technical.

Autologous manufacturing

Each Kymriah dose is manufactured from a specific patient’s cells. The process must manage:

• Leukapheresis collection
• Shipment to the manufacturing facility
• T-cell activation and genetic modification
• Cell expansion
• Formulation and filling
• Cryopreservation
• Release testing
• Shipment back to the treatment center
• Patient-specific chain of identity and chain of custody

Excipient changes can affect multiple points in this chain. A different DMSO grade, albumin source, cryobag, or freezing profile can require process validation and regulatory comparability work.

Release and stability testing

Commercial suppliers must support testing for:

• Viable cell count
• Viability after thaw
• CAR-positive cell percentage
• Potency
• Sterility
• Endotoxin
• Mycoplasma
• Identity
• Vector-related attributes
• Container integrity
• Stability under frozen storage and transport

The product’s shelf life and shipping conditions are part of the commercial value proposition. Excipient suppliers that provide stability data in the final product matrix have stronger negotiating leverage than those selling raw materials alone.

What are the commercial opportunities for Kymriah-related excipient suppliers?

The addressable market extends beyond Kymriah. Suppliers can sell into the broader CAR-T, TCR-T, NK-cell, stem-cell, and gene-modified cell-therapy markets.

Opportunity	Buyer	Revenue model	Strategic attractiveness
GMP-grade DMSO	Cell-therapy manufacturers and CDMOs	Recurring raw-material supply	Moderate; quality and continuity matter
HSA or recombinant albumin	Product sponsors and media manufacturers	Qualified-material contracts	High; qualification creates switching costs
Defined cryopreservation medium	Cell-therapy developers and CDMOs	Platform licensing or consumables	High; broader product applicability
Cryobags and fluid paths	Manufacturers, hospitals, CDMOs	Component sales and validation services	High; process integration supports retention
Cold-chain packaging	Logistics providers and treatment centers	Per-shipment and service contracts	Moderate to high
Cell-processing automation	CDMOs and treatment networks	Equipment, software, service, consumables	High; reduces labor and variability
Analytical services	Sponsors, CDMOs, hospitals	Testing and release support	High; complex assays support premium pricing
Albumin-free or low-DMSO formulations	Product developers	Licensing, co-development, supply	High but technically demanding

The strongest opportunity is a bundled platform combining formulation media, cryobags, controlled-rate freezing, thawing, and release analytics. Such a package can become part of a sponsor’s validated manufacturing process.

How does Kymriah compare with competing CAR-T products?

Kymriah competes with other CD19-directed CAR-T therapies, including Yescarta, Tecartus, and Breyanzi, as well as with non-CAR-T therapies. The relevant comparison is not simply the identity of the cryoprotectant.

Commercial factor	Kymriah	Implication for excipient suppliers
Product type	Autologous CAR-T	Patient-specific manufacturing and logistics
Primary target	CD19	Competition includes other CD19 products
Storage model	Cryopreserved cellular product	DMSO, albumin, cryobags, and transport are central
Manufacturing complexity	High	Validated materials command stronger customer retention
Substitution risk	Low at the excipient level after qualification	Supplier changes can be slow
Therapeutic substitution	High from competing CAR-T and bispecific antibodies	Product sponsors seek better turnaround, safety, and recovery
Key formulation goal	Preserve viable, potent cells through thaw and infusion	Post-thaw performance is more important than conventional dissolution

A formulation supplier does not need to win the Kymriah account alone. It can target the broader manufacturing ecosystem, including CDMOs and emerging cell-therapy developers that need platform materials before commercial launch.

What litigation and settlement issues affect Kymriah?

Kymriah-related legal exposure is more likely to involve CAR-T platform patents, licensing rights, manufacturing technology, and competing cellular therapies than Paragraph IV litigation over an Orange Book-listed formulation patent.

Relevant legal categories include:

• Patent disputes over CAR constructs and costimulatory domains
• License obligations associated with foundational CAR-T technology
• Ownership of engineered-cell inventions
• Manufacturing know-how and process patents
• Trade-secret claims involving cell-processing methods
• Patent challenges by competing CAR-T developers
• Contract disputes involving CDMOs and treatment networks

Paragraph IV challenges are generally not the central pathway for Kymriah because the product is not a conventional small-molecule drug with Orange Book-listed patents. A competitor may still challenge relevant patents through district-court litigation, inter partes review, post-grant review, or declaratory actions, depending on the patent and procedural posture.

What is Kymriah’s FDA and commercial status?

Kymriah remains an FDA-approved CAR-T therapy for specified B-cell malignancies. Its commercial performance depends on eligible patient volume, referral patterns, treatment-center capacity, manufacturing turnaround, reimbursement, safety management, and competition from other advanced therapies.

The product’s excipient-related commercial value is indirect. Novartis does not sell DMSO or HSA as standalone Kymriah products. Value accrues to suppliers that can improve:

• Manufacturing success rates
• Post-thaw viability
• Dose consistency
• Shipment reliability
• Turnaround time
• Cost of goods
• Treatment-center handling
• Regulatory comparability

Novartis reports Kymriah sales in its annual financial disclosures. Revenue exposure for excipient suppliers is therefore tied to total CAR-T manufacturing volume, not solely to Kymriah unit sales.[4]

What generic launch scenarios exist for Kymriah?

A conventional generic launch scenario is unlikely. The more realistic scenarios are:

1. A competing CD19 CAR-T product gains share through faster manufacturing or improved clinical performance.
2. An allogeneic CAR-T product reduces dependence on patient-specific production.
3. Bispecific antibodies capture patients who would otherwise receive CAR-T therapy.
4. Next-generation formulations reduce DMSO exposure or improve post-thaw recovery.
5. CDMOs standardize cryopreservation platforms across multiple sponsors.
6. A supplier achieves preferred status by validating its materials across several commercial cell therapies.

For excipient and formulation companies, the main risk is not a generic DMSO product. It is the replacement of autologous CAR-T manufacturing by a more scalable therapeutic platform.

Key Takeaways

• Kymriah uses a cryopreservation formulation centered on DMSO and human serum albumin.
• The formulation preserves living CAR-T cells rather than controlling conventional drug release.
• Qualified GMP-grade DMSO, albumin, defined cryopreservation media, cryobags, and closed fluid paths are the main commercial opportunities.
• Excipient changes can affect cell viability, potency, sterility, comparability, and regulatory filings.
• Kymriah is a biologic and is not subject to conventional Orange Book generic substitution.
• The principal competitive threat is from other CAR-T products, bispecific antibodies, and allogeneic cell therapies.
• The strongest supplier strategy is a validated platform combining formulation, container systems, cold-chain logistics, and analytical support.
• Kymriah’s most important IP barriers are likely to involve CAR constructs, manufacturing, cell compositions, and treatment methods rather than commodity excipient composition.
• US biologic reference-product exclusivity is generally associated with a period extending toward 2029 from the 2017 initial licensure, subject to statutory adjustments.
• The largest long-term opportunity is to supply the broader cell-therapy market rather than depend on one branded product.

FAQs

Can DMSO be replaced in Kymriah?

A DMSO reduction or replacement strategy is technically possible in cell therapy, but it would require evidence that post-thaw viability, phenotype, potency, sterility, stability, and infusion compatibility remain acceptable. A material change would require sponsor qualification and regulatory comparability work.

Is human serum albumin essential to Kymriah manufacturing?

HSA is identified in the US Kymriah formulation and provides protein stabilization and cell-protective functions. Alternative albumin sources or albumin-free systems could create commercial opportunities, but they would require product-specific validation.

Which suppliers benefit from CAR-T excipient demand?

The relevant supplier categories include pharmaceutical-grade DMSO manufacturers, HSA producers, recombinant albumin developers, defined cell-culture media companies, cryobag manufacturers, sterile-connectivity providers, cold-chain logistics companies, and cell-therapy analytical laboratories.

Does Kymriah have formulation exclusivity in the United States?

Kymriah’s commercial protection is not represented by a conventional Orange Book formulation-patent listing. Protection may arise from patents covering the cellular product, CAR design, manufacturing process, treatment method, and related technologies, while biologic reference-product exclusivity provides a separate regulatory barrier.

What is the best commercial entry point for a new Kymriah excipient supplier?

The most defensible entry point is a ready-to-use, GMP-qualified cryopreservation platform supported by cell-therapy-specific comparability data, container compatibility, stability testing, and supply continuity. Commodity pricing alone is unlikely to create durable value.

References

1. U.S. Food and Drug Administration. (2024). Kymriah (tisagenlecleucel) prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2020). Chemistry, manufacturing, and control information for human gene therapy investigational new drug applications. Center for Biologics Evaluation and Research.

3. U.S. Food and Drug Administration. (2023). Approval process for biosimilar and interchangeable biological products. Center for Drug Evaluation and Research.

4. Novartis AG. (2024). Annual report 2023. Basel, Switzerland: Novartis.